Tonix Pharmaceuticals Holding Corp (TNXP)
0.19
-0.01
(-6.95%)
USD |
NASDAQ |
Nov 22, 16:00
0.1807
-0.01
(-4.89%)
After-Hours: 20:00
Tonix Pharmaceuticals Cash from Financing (Quarterly): 42.90M for Sept. 30, 2024
Cash from Financing (Quarterly) Chart
Historical Cash from Financing (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 42.90M |
| June 30, 2024 | 7.025M |
| March 31, 2024 | -0.212M |
| December 31, 2023 | 40.71M |
| September 30, 2023 | 6.274M |
| June 30, 2023 | 1.029M |
| March 31, 2023 | -11.50M |
| December 31, 2022 | 7.229M |
| September 30, 2022 | -4.625M |
| June 30, 2022 | 72.18M |
| March 31, 2022 | 13.06M |
| December 31, 2021 | 43.77M |
| September 30, 2021 | 37.96M |
| June 30, 2021 | 22.05M |
| March 31, 2021 | 108.71M |
| December 31, 2020 | 39.86M |
| September 30, 2020 | 20.07M |
| June 30, 2020 | 34.42M |
| March 31, 2020 | 28.76M |
| December 31, 2019 | 7.914M |
| September 30, 2019 | 4.515M |
| June 30, 2019 | 0.417M |
| March 31, 2019 | 0.073M |
| December 31, 2018 | 17.19M |
| September 30, 2018 | 2.89M |
| Date | Value |
|---|---|
| June 30, 2018 | 2.93M |
| March 31, 2018 | 0.532M |
| December 31, 2017 | 1.118M |
| September 30, 2017 | 0.001M |
| June 30, 2017 | 16.30M |
| March 31, 2017 | 1.102M |
| December 31, 2016 | 4.857M |
| September 30, 2016 | 3.858M |
| June 30, 2016 | 11.78M |
| March 31, 2016 | 0.00 |
| December 31, 2015 | 0.00 |
| September 30, 2015 | 18.69M |
| June 30, 2015 | -0.054M |
| March 31, 2015 | 29.05M |
| December 31, 2014 | 0.303M |
| September 30, 2014 | 7.371M |
| June 30, 2014 | 0.131M |
| March 31, 2014 | 45.41M |
| December 31, 2013 | 4.321M |
| September 30, 2013 | 10.22M |
| June 30, 2013 | 0.406M |
| March 31, 2013 | 0.00 |
| December 31, 2012 | 3.255M |
| September 30, 2012 | 0.00 |
| June 30, 2012 | -0.00 |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (Quarterly) Range, Past 5 Years
-11.50M
Minimum
Mar 2023
108.71M
Maximum
Mar 2021
25.88M
Average
21.06M
Median
Cash from Financing (Quarterly) Benchmarks
| Abbott Laboratories | -1.576B |
| Emergent BioSolutions Inc | -180.30M |
| Geovax Labs Inc | 16.35M |
| Amicus Therapeutics Inc | 18.19M |
| Chimerix Inc | 0.178M |
Cash from Financing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -18.80M |
| Cash from Investing (Quarterly) | -0.009M |
| Free Cash Flow | -69.19M |
| Free Cash Flow Per Share (Quarterly) | -0.3028 |
| Free Cash Flow to Equity (Quarterly) | -18.31M |
| Free Cash Flow Yield | -2.06K% |